MOG disease, formally called myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), is an autoimmune condition in which the immune system attacks a protein on the outer surface of nerve insulation in the brain, spinal cord, and optic nerves. It affects roughly 1.3 to 2.5 people per 100,000 and was only recently recognized as a condition distinct from multiple sclerosis and other similar disorders.
How MOGAD Damages the Nervous System
Your nerve fibers are wrapped in a protective coating called myelin, which helps electrical signals travel quickly and efficiently. A small protein called MOG sits on the outermost layer of that coating. In MOGAD, the immune system produces antibodies that specifically target MOG, stripping myelin from the outside in.
Once the antibodies latch onto MOG, they trigger a chain reaction. Immune cells flood the area and begin destroying the myelin sheath through several parallel mechanisms: activating the complement system (a built-in alarm that recruits more immune cells), directly killing myelin-producing cells, and sending in macrophages that engulf and digest chunks of damaged myelin. As those macrophages break down myelin fragments, they present them to other immune cells, which ramps up the attack further. The result is large patches of demyelination that can form wherever MOG-coated nerve fibers exist.
One important distinction from other demyelinating diseases: MOGAD primarily destroys myelin without destroying the underlying support cells (astrocytes) that maintain the blood-brain barrier. This difference is one reason MOGAD often has a better recovery profile than conditions like neuromyelitis optica, where astrocyte destruction causes more permanent structural damage.
Common Symptoms
MOGAD can strike in three main patterns, depending on where inflammation occurs:
- Optic neuritis: Inflammation of one or both optic nerves, causing vision loss and eye pain that worsens with movement. This is the most common presentation in adults.
- Transverse myelitis: Inflammation of the spinal cord, leading to arm or leg weakness, muscle stiffness, paralysis, numbness, and changes in bladder, bowel, or sexual function. MOGAD-related spinal cord inflammation tends to affect the lower thoracic cord and the base of the spine.
- ADEM (acute disseminated encephalomyelitis): Widespread inflammation of the brain and spinal cord, causing confusion, vision loss, weakness, and an unsteady walk. This is the most common presentation in children.
Seizures, headaches, and fever can also occur. Children with MOGAD are more likely to have had a recent infection before their first attack, and their brain MRI often shows large, bilateral lesions in the temporal lobes and deep brain structures.
How MOGAD Differs From MS and NMOSD
For years, many people with MOGAD were misdiagnosed with multiple sclerosis or neuromyelitis optica spectrum disorder (NMOSD). These three conditions all damage myelin, but they behave differently in ways that matter for treatment and outlook.
On brain MRI, the differences are striking. Virtually all MS patients show white matter lesions in the brain, compared to only 27% of MOGAD patients. MS lesions cluster around the ventricles and in the corpus callosum, while MOGAD lesions, when present, tend to appear in deep gray matter and the cerebellar peduncles. A feature called the “central vein sign,” visible on specialized MRI sequences, appears in 84% of MS lesions but only 17% of MOGAD lesions.
MOGAD patients also tend to be younger at diagnosis and accumulate less long-term disability than those with NMOSD. In one comparative study, NMOSD patients had the worst visual outcomes and highest disability scores, while MOGAD patients had the shortest disease duration and the best functional scores overall.
How It’s Diagnosed
Diagnosis follows a three-step process established by international consensus. First, doctors confirm a core demyelinating event, such as optic neuritis, transverse myelitis, or ADEM. Second, they test for MOG antibodies in the blood using a live cell-based assay, which is the most reliable method available. Older testing methods like ELISA are not accurate enough for MOG antibodies and can produce misleading results. Third, they rule out MS and NMOSD, which require different treatment strategies.
If the antibody test comes back weakly positive rather than clearly positive, additional clinical and imaging criteria must be met before a diagnosis is made. This extra caution helps prevent false positives, since low-level MOG antibodies occasionally appear in people with other conditions.
Monophasic vs. Relapsing Course
One of the first questions people diagnosed with MOGAD ask is whether it will come back. The answer varies. Somewhere between 27% and 53% of patients experience relapses, while the rest have a single episode and recover. In a large review of 326 cases, 46% relapsed over an average follow-up of about four years.
MOGAD is more likely to follow a single-episode course than either MS or NMOSD, both of which are predominantly relapsing conditions. Higher antibody levels at diagnosis and a longer time before initial treatment may increase the risk of relapse, though predicting who will relapse and who won’t remains imprecise. In children, brain MRI improvements take longer in those with MOG antibodies, which may partly explain their higher tendency to relapse.
Treatment During Acute Attacks
When a MOGAD attack occurs, the standard first-line treatment is high-dose intravenous corticosteroids to rapidly reduce inflammation. For patients who don’t respond adequately, doctors may add intravenous immunoglobulin (IVIg) or plasma exchange, a procedure that filters harmful antibodies from the blood.
One pattern specific to MOGAD is the tendency for symptoms to flare up again when corticosteroids are tapered too quickly. Because of this, many specialists use a slow oral steroid taper over weeks to months after the initial intravenous course, rather than stopping abruptly.
Long-Term Relapse Prevention
For patients who experience repeated attacks, long-term immunosuppressive therapy can significantly reduce relapse rates. The three most commonly used medications each work by dampening different parts of the immune response.
In a systematic review of treatment outcomes, all three reduced the average number of relapses per year. Azathioprine reduced the annual relapse rate by 1.71 on average, while rituximab reduced it by 1.35 and mycophenolate by 0.83. Rituximab had the lowest rate of treatment discontinuation due to side effects at about 1.5%, compared to roughly 8% for mycophenolate and 11% for azathioprine. The choice between these options depends on the severity of relapses, how well someone tolerates each medication, and individual risk factors.
Who Gets MOGAD
MOGAD is rare but not as uncommon as once thought. Population-based studies from multiple countries put the prevalence at roughly 1.3 to 3.4 per 100,000 people. Incidence estimates range from about 1.6 to 4.8 new cases per million people per year. Children appear to be affected at higher rates than adults: a Dutch study found an incidence of 3.1 per million in children compared to 1.3 per million in adults.
The disease has been identified across all major racial and ethnic groups, with population studies reported from the UK, Italy, the Netherlands, Japan, Singapore, Thailand, the United States, and the Caribbean. There is no clear geographic hotspot comparable to the latitude gradient seen in MS.